Your browser doesn't support javascript.
loading
The Use of Immune Regulation in Treating Head and Neck Squamous Cell Carcinoma (HNSCC).
Wang, Che-Wei; Biswas, Pulak Kumar; Islam, Atikul; Chen, Mu-Kuan; Chueh, Pin Ju.
Afiliación
  • Wang CW; Institute of Biomedical Sciences, National Chung Hsing University, Taichung 40227, Taiwan.
  • Biswas PK; Department of Otorhinolaryngology-Head and Neck Surgery, Changhua Christian Hospital, Changhua 50006, Taiwan.
  • Islam A; Institute of Molecular Medicine, National Cheng Kung University, Tainan 70101, Taiwan.
  • Chen MK; Institute of Biomedical Sciences, National Chung Hsing University, Taichung 40227, Taiwan.
  • Chueh PJ; Department of Otorhinolaryngology-Head and Neck Surgery, Changhua Christian Hospital, Changhua 50006, Taiwan.
Cells ; 13(5)2024 Feb 27.
Article en En | MEDLINE | ID: mdl-38474377
ABSTRACT
Immunotherapy has emerged as a promising new treatment modality for head and neck cancer, offering the potential for targeted and effective cancer management. Squamous cell carcinomas pose significant challenges due to their aggressive nature and limited treatment options. Conventional therapies such as surgery, radiation, and chemotherapy often have limited success rates and can have significant side effects. Immunotherapy harnesses the power of the immune system to recognize and eliminate cancer cells, and thus represents a novel approach with the potential to improve patient outcomes. In the management of head and neck squamous cell carcinoma (HNSCC), important contributions are made by immunotherapies, including adaptive cell therapy (ACT) and immune checkpoint inhibitor therapy. In this review, we are focusing on the latter. Immune checkpoint inhibitors target proteins such as programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) to enhance the immune response against cancer cells. The CTLA-4 inhibitors, such as ipilimumab and tremelimumab, have been approved for early-stage clinical trials and have shown promising outcomes in terms of tumor regression and durable responses in patients with advanced HNSCC. Thus, immune checkpoint inhibitor therapy holds promise in overcoming the limitations of conventional therapies. However, further research is needed to optimize treatment regimens, identify predictive biomarkers, and overcome potential resistance mechanisms. With ongoing advancements in immunotherapy, the future holds great potential for transforming the landscape of oral tumor treatment and providing new hope for patients.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Carcinoma de Células Escamosas / Neoplasias de Cabeza y Cuello Límite: Humans Idioma: En Revista: Cells Año: 2024 Tipo del documento: Article País de afiliación: Taiwán Pais de publicación: Suiza
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Carcinoma de Células Escamosas / Neoplasias de Cabeza y Cuello Límite: Humans Idioma: En Revista: Cells Año: 2024 Tipo del documento: Article País de afiliación: Taiwán Pais de publicación: Suiza